Glycosidase regimen for treatment of infectious disease

a glycosidase and infectious disease technology, applied in the field of disease prevention, treatment and prevention of disease, can solve the problems of suppressing effect, harmful effect especially for hiv or aids patients, etc., and achieve the effects of enhancing vaccine effectiveness, convenient glycosidase dose applicator, and preventing or mitigating infectious diseases

Inactive Publication Date: 2015-08-27
KLINE ELLIS
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0012]In still other aspects, the invention provides a convenient glycosidase dose applicator. The applicator delivers a sufficient number of glycosidase doses for a non-acute regimen, such as for example, at least one month of doses for reversing viral disease trajectory or managing an infectious disease, or for preventing or mitigating infectious

Problems solved by technology

While ARVs can be an effective antiviral treatment ARV's have the adverse effect of s

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glycosidase regimen for treatment of infectious disease
  • Glycosidase regimen for treatment of infectious disease
  • Glycosidase regimen for treatment of infectious disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

HSV-1 Infectivity

[0078]Using HSV-1 as model virus, in vitro studies were initiated to determine the effect of neuraminidase and complement on viral infectivity and release from Vero cells. For infectivity studies, combinations of complement, virus and neuraminidase were incubated together, then added to Vero cells and incubated further. Following cell fixation and staining, the virus-forming plaques in the cells were counted. Results showed that incubating the virus with neuraminidase and complement together significantly (70-80%) reduced the virus' infectivity of Vero cells relative to controls (FIG. 1).

[0079]For Viral release studies, Vero cells were first infected with HSV-1. These cells were then incubated with various concentrations of complement and neuraminidase. Supernatants from the cell cultures were tested for plaque-forming ability, indicative of virus released from the cells. Results showed that, in the presence of both neuraminidase and complement, the release of free ...

example 2

Cytokine Release

[0080]The effect of neuraminidase on the production of certain cytokines in vitro was investigated. Cytokines are chemical messengers secreted by activated lymphocytes in response to infection. Any given cytokine, either alone or in combination with other cytokines, can have multiple effects on immune function. Interleukin-2 (IL-2), interferon alpha (IFN-α), interferon gamma (IFN-γ and tumor necrosis factor alpha (TNF-α) are important cytokines involved in host defense against viruses, IL-2, TNF-α and IFN-γ are produced by the T-helper (TH1) subset of T cells and are therefore associated with the inflammatory process. IL-2 and IFN-γ together activate macrophages, which are important immune cells that engulf and digest pathogens (phagocytosis), and also serve as antigen-presenting cells to T lymphocytes. IL-2 and IFN-γ also enhance the cytotoxicity of natural killer (NK) cells in clearing virally-infected cells. IFN-γ also enhances the expression of major histocompati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Login to view more

Abstract

In various aspects, the invention relates to immune tolerant glycosidase therapy. The invention provides methods for treating or preventing infectious disease, including chronic viral infections, and highly contagious infectious agents that present an ongoing challenge for the immune system. The compositions and treatment regimens find use with other antiviral or antimicrobial therapies, as well as in conjunction with vaccination to boost effectiveness and/or extend the duration of protective effect. In certain embodiments, the regimen described herein reduces or eliminates the need for administration of other traditional antiviral or antimicrobial therapies. In various embodiments, the invention finds use in immunocompromised patients to boost immune function.

Description

PRIORITY[0001]This Application claims priority to, and the benefit of, U.S. Provisional Application No. 61 / 707,252, which was filed Sep. 28, 2012, which is hereby incorporated by reference in its entirety.FIELD OF THE INVENTION[0002]The present invention relates to treatment and prevention of disease, and particularly the prevention, treatment and management of infectious disease, including chronic and non-chronic viral infections and other infectious disease with a glycosidase therapy.BACKGROUND[0003]Patients with chronic infections (such as chronic viral infections such as HIV, HSV, hepatitis virus, HPV, etc.) if effectively treated to reverse the disease trajectory or disease state, still require longterm disease management. However, continued administration of chemotherapeutic, monoclonal, or cytokine therapies can result in pathogen resistance, toxic effects for the patient including immune suppression, loss of effectiveness over time, and can be cost prohibitive for many patie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/00A61K45/06
CPCA61K45/06A61K39/00A61K38/47C12Y302/01018A61P1/04A61P11/00A61P11/02A61P11/04A61P11/08A61P13/02A61P27/02A61P27/16A61P31/04A61P31/06A61P31/10A61P31/12A61P31/14A61P31/18A61P31/20A61P31/22A61P33/00A61P33/02A61P33/06A61P37/02A61P43/00Y02A50/30C12Y302/01129A61K39/21A61K9/0053A61K9/006
Inventor KLINE, ELLIS
Owner KLINE ELLIS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap